Hypoglycemia risk and its impact on daily life is always present for people with diabetes and their caregivers (CG) . With the goal of positively impacting the lives of those who use insulin, advances in glucagon and its delivery, have made it ready-to-use, expanding the community of people who could act in an emergency. This qualitative study elicited experiences from people who own one option, nasal glucagon (NG) . Semi-structured 1:1 interviews were conducted in the US with AwD and CGs of children or AwD following a pre-defined concept elicitation guide and analyzed thematically. The sample included 22 AwD (20 T1DM; 2 T2DM) and 7 CGs of people with T1DM (1 Adult, 6 Children) ; female (72%) ; mean age 38.7 years; college degree 59%; insulin pump 62%. Actual use of NG was reported by 46% of AwD and 43% of CGs. A total of 45 concepts were identified, the majority (81%) identified by the first 5 interviews; saturation (the point at which no new concepts emerge) reached at 25 interviews. The most frequently stated concepts were: feeling safe having NG on hand (93%) ; ease of use for others (90%) ; comfort in having NG as a rescue treatment option (90%) ; confidence in others’ ability to use NG (86%) ; ease of instruction to others (86%) (Figure) . These firsthand experiences give useful clinical insights regarding NG, deepening our understanding for practice considerations.

graphic
View largeDownload slide
Disclosure

B.Mitchell: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. F.G.Sowell: None. P.Williams: None. J.Poon: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.

Funding

Eli Lilly and Company

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.